Katholieke Universiteit Leuven, Ku Leuven R&d

Vib Vzw

Imec

Katholieke Universiteit Leuven

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Vib Inc.

Wim Annaert

Bart De Strooper

Liesbet Lagae

Gustaaf Regina Borghs

Lujia Zhou

Patrik Verstreken

Sebastian Munck

Deepak Balaji Thimiri Govinda Raj

Ragna Sannerud

Katrijn Coen

Deepak Balaji Thimiri Govinda Ray

A method and apparatus for the imaging of a labeled biological sample. The method comprises illuminating the labeled biological sample, generating members of a time series of images if the labeled biological sample, generating a plurality of difference images between later members of the time series of images of earlier members of the time series of images and combining the plurality of difference images to generate a final image of the labeled biological sample.

Method and apparatus for the imaging of a labeled biological sample

The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

BACE1 inhibitory antibodies

The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group, or comprises a covalently bound hydrophilic layer bound to said nanoparticles.

Plasma membrane isolation

The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.

Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution

The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating the interaction.

Binding domains between presenilins and their substrates as targets for drug screening

Growing community of inventors

Kontich, Belgium

Wim Annaert